|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oquiñena S, GuillenGrima F, Iñarrairaegui
M, Zozaya JM and Sangro B: Spontaneous regression of hepatocellular
carcinoma: A systematic review. Eur J Gastroenterol Hepatol.
21:254–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huz JI, Melis M and Sarpel U: Spontaneous
regression of hepatocellular carcinoma is most often associated
with tumour hypoxia or a systemic inflammatory response. HPB
(Oxford). 14:500–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar A and Le DT: Hepatocellular
carcinoma regression after cessation of immunosuppressive therapy.
J Clin Oncol. 34:e90–e92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marquardt JU, GomezQuiroz L, Camacho LO
Arreguin, Pinna F, Lee YH, Kitade M, Domínguez MP, Castven D,
Breuhahn K, Conner EA, et al: Curcumin effectively inhibits
oncogenic NF-κB signaling and restrains stemness features in liver
cancer. J Hepatol. 63:661–669. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kowdley KV: Iron, hemochromatosis, and
hepatocellular carcinoma. Gastroenterology. 127:(5 Suppl 1).
S79–S86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nasr M, Selima E, Hamed O and Kazem A:
Targeting different angiogenic pathways with combination of
curcumin, leflunomide and perindopril inhibits
diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J
Pharmacol. 723:267–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sahasrabuddhe VV, Gunja MZ, Graubard BI,
Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND and
McGlynn KA: Nonsteroidal anti-inflammatory drug use, chronic liver
disease, and hepatocellular carcinoma. J Natl Cancer Inst.
104:1808–1814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Naegele H, Behnke B, Gebhardt A and
Strohbeck M: Effects of antihypertensive drugs on cholesterol
metabolism of human mononuclear leukocytes and hepatoma cells. Clin
Biochem. 31:37–45. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh S, Singh PP, Singh AG, Murad MH and
Sanchez W: Anti-diabetic medications and the risk of hepatocellular
cancer: A systematic review and meta-analysis. Am J Gastroenterol.
108:881–891; quiz 892. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: Taking away
the candy for cancer? Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai SW, Liao KF, Lai HC, Muo CH, Sung FC
and Chen PC: Statin use and risk of hepatocellular carcinoma. Eur J
Epidemiol. 28:485–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
